Selected Publications
Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, Ketchum SB, Doyle RT Jr, Tardif JC, Ballantyne CM.: Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn Eur Heart J Open 3 (6): 2023.
Chukwurah MI, Miller M: Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering? Curr Cardiol Rep : 2023.
Bhatt DL, Bays HE, Miller M, Cain JE 3rd, Wasilewska K, Andrawis NS, Parli T, Feng S, Sterling L, Tseng L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP;: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. ENTRIGUE Principal Investigators Nat Med : 2023.
Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif JC, Ballantyne CM, Chung MK; REDUCE‐IT Investigators.: Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. J Am Heart Assoc : 2023.
Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Ballantyne CM, Budoff M, Mason RP; REDUCE-IT Investigators.: Potential Effects of Icosapent Ethyl on Cardiovascular Outcomes in Cigarette Smokers: REDUCE-IT Smoking. Eur Heart J Cardiovasc Pharmacother : 2023.
Miller M: REDUCE-IT: Findings and Implications for Practice Br J Cardiol : 2023.
Miller M, Bhatt DL, Brinton EA, et al.: Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in the Metabolic Syndrome: REDUCE-IT MetSyn Circulation : 2023.
Miller M on behalf of the authors Bhatt DL, Bays HE, Parli T, Feng S, Sterling L, Hartsfield CL, Agollah GD, Mansbach H, Kastelein JJP.: Phase 2 trial of pegozafermin in severe hypertriglyceridemia Presented at the Annual National Lipid Association Scientific Sessions, Atlanta, GA : 2023.
Alfaddagh A, Kapoor K, Dardari ZA, Bhatt DL, Budoff MJ, Nasir K, Miller M, Welty FK, Miedema MD, Shapiro MD, Tsai MY, Blumenthal RS, Blaha MJ.: Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis : 2022.
Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Bhatt DL.: Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation : 2022.
Academic Contact Information
Michael J. Crescenz Veteran’s Affairs Medical Center
3900 Woodland Avenue
Philadelphia,
PA
19104
Phone: 410-905-5584
Patient appointments: 800-789-7366